A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk
Maria J Redondo, Susan Geyer, Andrea K Steck, Seth Sharp, John M Wentworth, Michael N Weedon, Peter Antinozzi, Jay Sosenko, Mark Atkinson, Alberto Pugliese, Richard A Oram
Diabetes Care | AMER DIABETES ASSOC | Published : 2018
OBJECTIVE: We tested the ability of a type 1 diabetes (T1D) genetic risk score (GRS) to predict progression of islet autoimmunity and T1D in at-risk individuals. RESEARCH DESIGN AND METHODS: We studied the 1,244 TrialNet Pathway to Prevention study participants (T1D patients' relatives without diabetes and with one or more positive autoantibodies) who were genotyped with Illumina ImmunoChip (median [range] age at initial autoantibody determination 11.1 years [1.2-51.8], 48% male, 80.5% non-Hispanic white, median follow-up 5.4 years). Of 291 participants with a single positive autoantibody at screening, 157 converted to multiple autoantibody positivity and 55 developed diabetes. Of 953 partic..View full abstract
Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awarded by National Health and Medical Research Council Fellowship
Awarded by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
The sponsor of the trial was the T1D TrialNet Study Group, which is a clinical trials network funded by the National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085509, U01 DK103180, U01 DK103153, U01 DK085476, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK106994, U01 DK107013, U01 DK107014, and UC4 DK106993) and JDRF. J.M.W. was funded by a JDRF Australia Clinical Practitioner Fellowship and National Health and Medical Research Council Fellowship 1078106. R.A.O. was funded by the Diabetes UK Harry Keen Fellowship.